LifeSci Capital Starts Inhibrx Biosciences (INBX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts INBX Hot Sheet
Price: $72.16 +0.53%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
LifeSci Capital initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Outperform rating and a price target of $200.00.
For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.
Shares of Inhibrx Biosciences closed at $119.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Starts Zhongji Innolight Co Ltd (3308:HK) at Buy
- CLSA Upgrades Marico Ltd (MRCO:IN) to Hold (3)
- Kotak Upgrades Escorts Kubota Ltd (ESCORTS:IN) to Buy (1)
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
